BioAge is a well-funded, high-risk clinical biotech where BGE-102 could become a best-in-class oral anti-inflammatory platform—or expose shareholders to binary trial downside.
Overview
BioAge Labs is a clinical-stage biotech using human longevity datasets and machine learning to discover therapies for aging-linked metabolic and inflammatory diseases. With no approved products, revenue comes from collaborations, especially Novartis. The investment case centers on BGE-102, an oral NLRP3 inhibitor with strong Phase 1 inflammation biomarker reductions, and APJ agonists as exercise mimetics. Large cardiovascular, retinal, and obesity markets create major upside, but clinical risk remains high.